NCT05174806View on ClinicalTrials.gov

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Diabetic Foot InfectionDiabetic Foot
Interventions
DRUG

Topical Pravibismane

Topical Pravibismane

OTHER

Standard of Care

Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.

Trial Locations (7)

75235

Parkland Comprehensive Wound Center, Dallas

Parkland Memorial Hospital, Dallas

75390

University of Texas Southwestern Medical Center University Wound Care Clinic, Dallas

University of Texas Southwestern Medical Center William P. Clements Jr. University Hospital, Dallas

78224

Bio-X-Cell Research, San Antonio

78501

Futuro Clinical Trials, LLC, McAllen

93710

Limb Preservation Platform, Inc., Fresno

Sponsors

Collaborators (1)

CUBRC
All Listed Sponsors
collaborator

CUBRC

UNKNOWN

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

collaborator

MTEC

UNKNOWN

lead

Microbion Corporation

INDUSTRY

NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients | Biotech Hunter | Biotech Hunter